HemoShear Therapeutics Identifies Novel Drug Target to Treat NASH in Drug Discovery Partnership with Takeda
Drug Target Will Advance into Takeda s Discovery Portfolio as Part of Ongoing Collaboration
News provided by
Share this article
Share this article
CHARLOTTESVILLE, Va., Dec. 10, 2020 /PRNewswire/ HemoShear Therapeutics, LLC, a privately held clinical stage biotechnology company, has achieved a research milestone in its discovery and development collaboration with Takeda Pharmaceutical Company Limited ( Takeda ) to advance its first nonalcoholic steatohepatitis (NASH) target into Takeda s discovery portfolio. Using the company s
REVEAL-Tx™ human disease modeling platform, HemoShear is collaborating with Takeda to identify and validate novel drug targets for treating NASH. In accordance with the collaboration agreement executed in October 2017, HemoShear will receive an undisclosed milestone payment.